Elite Journal of Health Sciences. Volume 2 issue 2(2024), Pp. 40-49
https://epjournals.com/journals/EJHS

Hemoglobin Dynamics: Unraveling the Role in Monitoring Breast Cancer Evolution

[*]Emmanuel Ifeanyi Obeagu1, I.S.I Ogbu[2] and Getrude Uzoma Obeagu[3]

[1]Department of Medical Laboratory Science, Kampala International University, Uganda

[2]School of Nursing Science, Kampala International University, Uganda

[3]Department of Medical Laboratory Science, Evangel University Akaeze, Ebonyi State, Nigeria.

[*]Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

Breast cancer remains a complex and multifaceted disease, necessitating the identification of novel biomarkers for effective monitoring of its evolution. This paper explores the evolving role of hemoglobin variations as a potential indicator in understanding and tracking breast cancer progression. Hemoglobin, primarily recognized for its oxygen transport function, has emerged as a promising biomarker due to its dynamic alterations within the tumor microenvironment. Through an extensive synthesis of current literature, this review elucidates the intricate relationship between hemoglobin fluctuations and breast cancer evolution. It discusses the molecular mechanisms underlying hemoglobin modifications, their correlation with tumor characteristics, and their clinical implications for disease monitoring. Furthermore, it outlines the diagnostic potential of hemoglobin indices in guiding treatment strategies, predicting patient outcomes, and enhancing personalized medicine in breast cancer management. However, challenges persist in standardizing measurement techniques and interpreting hemoglobin variations accurately. This review also identifies these limitations and proposes future research directions to optimize the clinical utility of hemoglobin as a biomarker for monitoring breast cancer evolution. In conclusion, understanding the significance of hemoglobin dynamics offers a promising avenue for refining prognostication, treatment assessment, and improving overall outcomes in breast cancer patients.

Keywords: *Hemoglobin, Breast Cancer, Tumor Microenvironment, Disease Evolution, Biomarkers, Clinical Implications, Precision Medicine*

Introduction

Citation: Obeagu EI, Ogbu ISI, Obeagu GU. Hemoglobin Dynamics: Unraveling the Role in Monitoring Breast Cancer Evolution. Elite Journal of Health Science, 2024; 2(2): 40-49

Breast cancer stands as a formidable challenge in contemporary oncology, characterized by its heterogeneity and varying clinical trajectories.[1] The quest for reliable biomarkers to comprehensively monitor disease progression and treatment response remains a pressing need in the field. Amidst this pursuit, hemoglobin, classically acknowledged for its role in oxygen transport, has emerged as a potential biomarker offering insights into the dynamic landscape of breast cancer evolution.[2] Traditionally, biomarkers in breast cancer have revolved around genetic mutations, protein expression, and imaging modalities, each with its limitations in capturing the nuanced changes occurring within the tumor microenvironment.[3] However, recent investigations have uncovered compelling evidence linking alterations in hemoglobin levels, structure, and function to the intricacies of tumor biology and disease progression. This paradigm shift has prompted a reevaluation of hemoglobin's significance beyond its canonical role, directing attention toward its potential utility in monitoring breast cancer evolution.[4]

The tumor microenvironment, a complex milieu comprising stromal cells, vasculature, and immune components, exerts a profound influence on tumor behavior and treatment response.[5] Hemoglobin, existing not only within erythrocytes but also in the tumor microenvironment, has been implicated in modulating various aspects of cancer pathophysiology, including angiogenesis, hypoxia response, and metastasis.[6] Understanding the interplay between hemoglobin dynamics and the tumor microenvironment offers a unique perspective into the evolving landscape of breast cancer. This paper aims to synthesize the current understanding of hemoglobin variations as a potential window into monitoring breast cancer evolution. It delves into the molecular intricacies governing hemoglobin alterations within the tumor milieu, elucidates their associations with disease characteristics, and discusses their clinical implications in disease monitoring and prognostication. Furthermore, it addresses the challenges and prospects of harnessing hemoglobin as a biomarker, paving the way for future research directions to refine its clinical applicability. In essence, exploring the evolving role of hemoglobin in the context of breast cancer represents a promising avenue toward enhancing our comprehension of disease dynamics, refining treatment strategies, and ultimately improving outcomes for individuals grappling with this formidable malignancy.

Hemoglobin

Hemoglobin, an intricate and pivotal protein molecule, is primarily recognized for its fundamental role in transporting oxygen from the lungs to tissues throughout the body. Comprising four globin protein subunits—each binding to a heme group containing iron—hemoglobin molecules efficiently bind and release oxygen in response to variations in oxygen tension.[7] In addition to its oxygen-carrying function, hemoglobin has garnered attention for its relevance beyond erythrocytes (red blood cells) within the context of cancer biology and disease progression. Emerging evidence suggests that hemoglobin and its alterations play a more intricate role in the tumor microenvironment, contributing to various facets of cancer development, progression, and treatment response.[7] The tumor microenvironment, characterized by its dynamic interplay of cells, blood vessels, and signaling molecules, significantly influences cancer behavior. Within this milieu, hemoglobin interacts with factors related to hypoxia, angiogenesis, and the immune response, thereby influencing the growth, survival, and metastatic potential of cancer cells. Changes in hemoglobin levels, structural modifications, or interactions with hypoxia-inducible

factors (HIFs) and angiogenic mediators contribute to the tumor's adaptive responses and may serve as indicators of disease aggressiveness or treatment resistance.[8]

In breast cancer, alterations in hemoglobin levels or related indices are being investigated as potential biomarkers reflective of the tumor microenvironment and disease progression. Elevated or reduced hemoglobin levels, along with changes in associated parameters like hematocrit, mean corpuscular volume (MCV), or red cell distribution width (RDW), have shown correlations with tumor characteristics, treatment response, and patient outcomes. Furthermore, these variations in hemoglobin dynamics may hold promise as non-invasive markers for prognostication and monitoring therapeutic interventions.[9] Understanding the intricate relationships between hemoglobin alterations, tumor biology, and the evolving landscape of breast cancer is paving the way for exploring new avenues in precision medicine. Harnessing the potential of hemoglobin as a biomarker offers prospects for refining diagnostic approaches, predicting treatment responses, and tailoring therapies to individual patient profiles, ultimately contributing to improved management strategies and outcomes in breast cancer care.

Breast Cancer

Breast cancer represents one of the most prevalent malignancies globally, affecting both women and, albeit less frequently, men. It arises when cells in the breast begin to grow uncontrollably, forming a tumor that may invade nearby tissues or spread (metastasize) to distant parts of the body. This disease exhibits diverse characteristics, encompassing various subtypes with distinct molecular profiles, behaviors, and responses to treatment.[10] Several risk factors contribute to the development of breast cancer, including genetic predispositions (such as mutations in BRCA1 and BRCA2 genes), family history, hormonal influences, lifestyle factors (like obesity, alcohol consumption, and lack of physical activity), and environmental exposures.[11] Early-stage breast cancer may not display noticeable symptoms, emphasizing the critical role of screening mammograms and self-examinations for timely detection. As the disease progresses, symptoms might include a lump or thickening in the breast or underarm, changes in breast size or shape, nipple abnormalities, skin dimpling, redness, or nipple discharge. However, these signs are not exclusive to breast cancer and can be related to benign conditions.[12]

The diagnosis of breast cancer involves a combination of imaging tests (mammograms, ultrasounds, MRIs) and biopsy procedures to confirm the presence of cancerous cells and determine the cancer's characteristics, such as its hormone receptor status (estrogen and progesterone receptors) and human epidermal growth factor receptor 2 (HER2/neu) status. These factors guide treatment decisions and influence prognosis.[13] Treatment strategies for breast cancer vary based on the cancer stage, subtype, and individual patient factors. Common approaches include surgery (lumpectomy or mastectomy), radiation therapy, chemotherapy, hormone therapy, targeted therapy (such as HER2-targeted drugs), and immunotherapy. The treatment plan often involves a combination of these modalities tailored to the specific needs of each patient.[14] Advances in research have led to the development of more targeted therapies and personalized treatment approaches, leading to improved outcomes and survival rates, especially when diagnosed at earlier stages. Additionally, ongoing research focuses on understanding the molecular mechanisms driving breast cancer progression, identifying novel biomarkers, and exploring

innovative treatment strategies to further enhance patient outcomes and quality of life.[15] Breast cancer management involves not only medical interventions but also comprehensive care that considers psychological, emotional, and supportive aspects for patients and their families.[16] Awareness, early detection, access to quality healthcare, and advancements in treatment options collectively contribute to the ongoing efforts to combat breast cancer and improve the lives of those affected by this disease.

Hemoglobin and Tumor Microenvironment

Hemoglobin, a vital protein responsible for transporting oxygen in the bloodstream, has increasingly drawn attention for its roles beyond oxygen delivery within the complex context of the tumor microenvironment. The tumor microenvironment represents the cellular and molecular landscape surrounding tumors, encompassing a dynamic interplay of cancer cells, stromal cells, blood vessels, immune cells, and signaling molecules.[17] In the context of the tumor microenvironment, hemoglobin alterations and their interactions play a multifaceted role in influencing various aspects of cancer biology and tumor progression. Hemoglobin contributes significantly to tissue oxygenation, and alterations in its levels or function can impact the oxygen availability within the tumor microenvironment. Regions of inadequate oxygen supply (hypoxia) often occur within solid tumors due to rapid cell growth and limited blood vessel formation. Hypoxia triggers adaptive responses in cancer cells, promoting aggressive behavior, angiogenesis (new blood vessel formation), metastasis, and resistance to therapies.[18] Hemoglobin and its derivatives, particularly through interactions with hypoxia-inducible factors (HIFs), influence the process of angiogenesis. Hypoxia-driven upregulation of HIFs leads to the release of angiogenic factors, promoting the formation of new blood vessels to supply the growing tumor with nutrients and oxygen. Hemoglobin's involvement in this process can affect tumor growth and metastatic potential.[19]

Hemoglobin and its breakdown products, including heme and iron, can impact immune responses within the tumor microenvironment. These molecules may modulate immune cell function and polarization, potentially influencing antitumor immune responses and tumor progression.[19] Hemoglobin, through its iron-containing heme groups, can contribute to redox reactions and oxidative stress within tumors. This oxidative stress may affect cellular signaling pathways, DNA damage, and metabolic processes, influencing tumor cell behavior.[21] Understanding the intricate relationships between hemoglobin alterations and the tumor microenvironment is crucial for unraveling the complexities of cancer biology and developing targeted therapeutic strategies. Research aimed at elucidating these interactions may lead to novel approaches in cancer treatment, such as targeting hemoglobin-related pathways to modulate the tumor microenvironment, improve oxygenation, and enhance the efficacy of existing therapies. Additionally, investigating hemoglobin as a potential biomarker for assessing tumor hypoxia and treatment response holds promise in guiding personalized cancer therapies.

Clinical Implications and Diagnostic Potential

The clinical implications and diagnostic potential of hemoglobin variations within the context of breast cancer are becoming increasingly recognized in oncology. Hemoglobin, traditionally regarded as a fundamental component in oxygen transport, is now being investigated for its potential as a biomarker to monitor disease progression, guide treatment decisions, and predict patient outcomes.[22] Alterations in hemoglobin levels, along with associated parameters like hematocrit, mean corpuscular volume (MCV), or red cell distribution width (RDW), have demonstrated correlations with various aspects of breast cancer. Changes in these hemoglobin-related indices have been associated with tumor characteristics, disease stage, aggressiveness, and prognosis. Monitoring these variations over time may offer insights into disease progression and help stratify patients for appropriate interventions.[23] Hemoglobin dynamics have shown promise in predicting and assessing responses to different therapeutic modalities. Studies suggest that pre-treatment hemoglobin levels or alterations during treatment could serve as indicators of treatment efficacy or resistance. Monitoring hemoglobin changes alongside treatments like chemotherapy, radiation therapy, or targeted therapies may assist clinicians in evaluating treatment responses and modifying strategies accordingly.[24-25] Understanding the relationship between hemoglobin variations and breast cancer subtype characteristics (such as hormone receptor status, HER2 status) could contribute to personalized risk assessment. Elevated or reduced hemoglobin levels might be indicative of specific molecular subtypes or phenotypic features, aiding in tailoring treatment approaches based on individual patient profiles.

Hemoglobin-related indices, being easily accessible through routine blood tests, offer the advantage of non-invasive assessment. This presents an opportunity for integrating hemoglobin variations into routine clinical assessments, potentially complementing existing imaging and molecular biomarkers for a more comprehensive evaluation of disease status.[26] Hemoglobin levels have also been associated with long-term outcomes and survivorship in breast cancer patients. Lower pre-treatment hemoglobin levels have been linked to poorer overall survival and disease-free survival rates, highlighting their prognostic significance beyond initial diagnosis and treatment phases.[27] Despite these promising aspects, several challenges exist, including the need for standardized measurement methods, consideration of confounding factors influencing hemoglobin levels, and integration into clinical practice guidelines. Further research endeavors are essential to validate and refine the clinical utility of hemoglobin variations as reliable biomarkers in breast cancer management.[28] The diagnostic potential and clinical implications of hemoglobin variations in breast cancer represent a promising avenue for enhancing patient care. Integrating hemoglobin-related parameters into clinical decision-making processes holds the potential to refine risk stratification, predict treatment responses, and improve overall outcomes in the management of breast cancer patients.

Challenges and Future Directions

The exploration of hemoglobin variations as potential biomarkers for monitoring breast cancer evolution presents several challenges and prompts considerations for future research directions aimed at optimizing their clinical utility. Variability in measurement methods, laboratory assays, and instruments used to assess hemoglobin levels poses a challenge in achieving consistency and comparability across studies. Establishing standardized protocols for measuring hemoglobin

variations is crucial to ensure reliability and facilitate meaningful comparisons between different research findings. While hemoglobin variations show correlations with breast cancer characteristics and outcomes, understanding the nuances of these changes is essential. Factors beyond cancer, such as comorbidities, nutritional status, inflammation, and other physiological conditions, can influence hemoglobin levels. Disentangling these confounding factors from cancer-specific changes is crucial for accurate interpretation.[29]

Conducting large-scale longitudinal studies that track hemoglobin dynamics across various stages of breast cancer, treatment modalities, and patient populations is essential. These studies can validate the predictive value of hemoglobin alterations in assessing disease progression, treatment response, and long-term outcomes. Hemoglobin variations should be integrated into comprehensive multimodal biomarker panels that include imaging, genetic, proteomic, and other molecular markers. Combining hemoglobin-related indices with existing biomarkers could enhance the accuracy and predictive power of diagnostic and prognostic models in breast cancer.[30-31]

Investigating the mechanistic links between hemoglobin alterations and tumor biology offers opportunities for targeted interventions. Understanding how manipulating hemoglobin levels or related pathways affects tumor behavior could pave the way for innovative therapeutic strategies to modulate the tumor microenvironment and improve treatment outcomes. Validating the clinical utility of hemoglobin variations in large-scale prospective studies is necessary before integrating them into clinical guidelines. Establishing clear guidelines and algorithms for interpreting hemoglobin-related parameters in breast cancer management will aid clinicians in making informed decisions.[30] Advancements in technology, including point-of-care testing and miniaturized devices, could facilitate real-time monitoring of hemoglobin variations in clinical settings. These innovations would enhance accessibility, convenience, and timely assessment, particularly in resource-limited settings. Addressing these challenges and advancing research along these trajectories will refine our understanding of hemoglobin's role in breast cancer evolution and optimize its clinical translation. This concerted effort holds promise for enhancing the precision and effectiveness of breast cancer management through the incorporation of hemoglobin-related biomarkers into routine clinical practice.[32-45]

Recommendations

Based on the challenges and future directions outlined in the exploration of hemoglobin variations in monitoring breast cancer evolution, several key recommendations emerge to further advance research and enhance clinical applications Encourage interdisciplinary collaboration among researchers, clinicians, oncologists, hematologists, and experts in tumor biology to pool resources, expertise, and data. Collaborative efforts facilitate the design of comprehensive studies, promote standardization of methodologies, and accelerate the translation of research findings into clinical practice. Prioritize the design and implementation of large-scale longitudinal studies involving diverse cohorts of breast cancer patients. These studies should encompass different subtypes, stages of disease, treatment modalities, and diverse demographic backgrounds to validate the clinical relevance of hemoglobin variations across varied populations and clinical scenarios.

Invest in the development of innovative technologies for precise and convenient measurement of hemoglobin levels or related parameters. Advancements in point-of-care testing, wearable devices, and remote monitoring tools can facilitate real-time monitoring of hemoglobin dynamics, enabling timely interventions and personalized patient care. Establish standardized protocols and guidelines for measuring, interpreting, and integrating hemoglobin-related indices into clinical practice. This includes defining thresholds for significant changes in hemoglobin levels, considering factors affecting measurements, and incorporating these biomarkers into existing clinical guidelines for breast cancer management. Increase awareness among healthcare professionals, clinicians, and patients about the potential role of hemoglobin variations as biomarkers in breast cancer monitoring. Education programs and workshops could emphasize the importance of these biomarkers, their implications in disease management, and their role in personalized treatment strategies. Encourage translational research focused on elucidating the underlying mechanisms linking hemoglobin alterations to tumor biology. Investigate the feasibility of targeted interventions aimed at modulating hemoglobin-related pathways to improve treatment responses and patient outcomes in breast cancer.

Support from regulatory bodies and increased funding for research initiatives exploring hemoglobin variations in breast cancer are critical. Encourage funding agencies and regulatory bodies to prioritize and support studies investigating hemoglobin-related biomarkers for their potential clinical applications. By addressing these recommendations, the scientific and medical communities can collectively advance the understanding of hemoglobin variations in breast cancer and leverage this knowledge to develop more effective strategies for disease monitoring, treatment optimization, and improved outcomes for patients.

Conclusion

The exploration of hemoglobin variations as potential biomarkers for monitoring breast cancer evolution represents a promising frontier in oncology. The multifaceted roles of hemoglobin within the tumor microenvironment, extending beyond its classical function in oxygen transport, offer insights into the complex dynamics of cancer biology and disease progression. The growing body of evidence linking hemoglobin alterations to various aspects of breast cancer—ranging from tumor characteristics and treatment responses to patient outcomes—underscores the potential clinical relevance of these biomarkers. However, harnessing the full potential of hemoglobin-related indices in breast cancer management necessitates overcoming challenges, embracing collaborative efforts, and pursuing targeted research initiatives.

The prospects offered by hemoglobin-related biomarkers in breast cancer monitoring hold promise for enhancing personalized medicine, refining treatment strategies, and ultimately improving patient outcomes. As research progresses and these recommendations are implemented, the integration of hemoglobin variations into routine clinical assessments could significantly augment the precision and effectiveness of breast cancer management, ushering in a new era of tailored and more effective patient care. Continued dedication to understanding hemoglobin's role in breast cancer will further propel advancements towards optimized therapies and improved quality of life for individuals affected by this challenging disease.

Citation: Obeagu EI, Ogbu ISI, Obeagu GU. Hemoglobin Dynamics: Unraveling the Role in Monitoring Breast Cancer Evolution. Elite Journal of Health Science, 2024; 2(2): 40-49

References

1. Ng CK, Schultheis AM, Bidard FC, Weigelt B, Reis-Filho JS. Breast cancer genomics from microarrays to massively parallel sequencing: paradigms and new insights. Journal of the National Cancer Institute. 2015;107(5): djv015.
2. Khan R, Parihar A, Sanghi SK, editors. Biosensor Based Advanced Cancer Diagnostics: From Lab to Clinics. Academic Press; 2021.
3. Bi WL, Hosny A, Schabath MB, Giger ML, Birkbak NJ, Mehrtash A, Allison T, Arnaout O, Abbosh C, Dunn IF, Mak RH. Artificial intelligence in cancer imaging: clinical challenges and applications. CA: a cancer journal for clinicians. 2019;69(2):127-57.
4. Ferrer CM, Sodi VL, Reginato MJ. O-GlcNAcylation in cancer biology: linking metabolism and signaling. Journal of molecular biology. 2016;428(16):3282-94.
5. Turley SJ, Cremasco V, Astarita JL. Immunological hallmarks of stromal cells in the tumour microenvironment. Nature reviews immunology. 2015;15(11):669-82.
6. Horsman MR, Vaupel P. Pathophysiological basis for the formation of the tumor microenvironment. Frontiers in oncology. 2016; 6:66.
7. Ahmed MH, Ghatge MS, Safo MK. Hemoglobin: structure, function and allostery. Vertebrate and invertebrate respiratory proteins, lipoproteins and other body fluid proteins. 2020:345-82.
8. Sanegre S, Lucantoni F, Burgos-Panadero R, de La Cruz-Merino L, Noguera R, Álvaro Naranjo T. Integrating the tumor microenvironment into cancer therapy. Cancers. 2020;12(6):1677.
9. Brassart-Pasco S, Brézillon S, Brassart B, Ramont L, Oudart JB, Monboisse JC. Tumor microenvironment: extracellular matrix alterations influence tumor progression. Frontiers in oncology. 2020; 10:397.
10. Benson JR, Jatoi I. The global breast cancer burden. Future oncology. 2012;8(6):697-702.
11. Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, Ji X, Liu W, Huang B, Luo W, Liu B. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes & diseases. 2018;5(2):77-106.
12. Dey S. Preventing breast cancer in LMICs via screening and/or early detection: The real and the surreal. World journal of clinical oncology. 2014;5(3):509.
13. Zubair M, Wang S, Ali N. Advanced approaches to breast cancer classification and diagnosis. Frontiers in Pharmacology. 2021; 11:632079.
14. Łukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanisławek A. Breast cancer—epidemiology, risk factors, classification, prognostic markers, and current treatment strategies—an updated review. Cancers. 2021;13(17):4287.
15. Yen TT, Wang TL, Fader AN, Shih IM, Gaillard S. Molecular classification and emerging targeted therapy in endometrial cancer. International journal of gynecological pathology: official journal of the International Society of Gynecological Pathologists. 2020;39(1):26.
16. Runowicz CD, Leach CR, Henry NL, Henry KS, Mackey HT, Cowens-Alvarado RL, Cannady RS, Pratt-Chapman ML, Edge SB, Jacobs LA, Hurria A. American cancer society/American society of clinical oncology breast cancer survivorship care guideline. CA: a cancer journal for clinicians. 2016;66(1):43-73.

17. Gulzar A, Xu J, Wang C, He F, Yang D, Gai S, Yang P, Lin J, Jin D, Xing B. Tumour microenvironment responsive nanoconstructs for cancer theranostic. Nano today. 2019; 26:16-56.
18. Vaupel P, Mayer A, Höckel M. Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlentherapie und Onkologie. 2006;182(2):63-71.
19. Jain T, Nikolopoulou EA, Xu Q, Qu A. Hypoxia inducible factor as a therapeutic target for atherosclerosis. Pharmacology & therapeutics. 2018; 183:22-33
20. Sacco A, Battaglia AM, Botta C, Aversa I, Mancuso S, Costanzo F, Biamonte F. Iron metabolism in the tumor microenvironment—implications for anti-Cancer immune response. Cells. 2021;10(2):303.
21. Salnikow K. Role of iron in cancer. InSeminars in Cancer Biology 2021; 76:189-194. Academic Press.
22. Pasculli B, Barbano R, Parrella P. Epigenetics of breast cancer: Biology and clinical implication in the era of precision medicine. InSeminars in cancer biology 2018; 51: 22-35. Academic Press.
23. Li Y, Wu H, Xing C, Hu X, Zhang F, Peng Y, Li Z, Lu T. Prognostic evaluation of colorectal cancer using three new comprehensive indexes related to infection, anemia and coagulation derived from peripheral blood. Journal of Cancer. 2020;11(13):3834.
24. Ho CS, Lim LJ, Lim AQ, Chan NH, Tan RS, Lee SH, Ho RC. Diagnostic and predictive applications of functional near-infrared spectroscopy for major depressive disorder: a systematic review. Frontiers in psychiatry. 2020; 11:378.
25. Dewhirst MW, Thrall DE, Palmer G, Schroeder T, Vujaskovic Z, Cecil Charles H, Macfall J, Wong T. Utility of functional imaging in prediction or assessment of treatment response and prognosis following thermotherapy. International Journal of Hyperthermia. 2010;26(3):283-93.
26. Taylor-Williams M, Spicer G, Bale G, Bohndiek SE. Noninvasive hemoglobin sensing and imaging: optical tools for disease diagnosis. Journal of Biomedical Optics. 2022;27(8):080901-.
27. Moore HC. Breast cancer survivorship. InSeminars in Oncology 2020;47(4):222-228. WB Saunders.
28. Bevans M, El-Jawahri A, Tierney DK, Wiener L, Wood WA, Hoodin F, Kent EE, Jacobsen PB, Lee SJ, Hsieh MM, Denzen EM. National Institutes of Health hematopoietic cell transplantation late effects initiative: the patient-centered outcomes working group report. Biology of Blood and Marrow Transplantation. 2017;23(4):538-51.
29. Taylor-Williams M, Spicer G, Bale G, Bohndiek SE. Noninvasive hemoglobin sensing and imaging: optical tools for disease diagnosis. Journal of Biomedical Optics. 2022;27(8):080901-.
30. Taksler GB, Dalton JE, Perzynski AT, Rothberg MB, Milinovich A, Krieger NI, Dawson NV, Roach MJ, Lewis MD, Einstadter D. Opportunities, pitfalls, and alternatives in adapting electronic health records for health services research. Medical Decision Making. 2021;41(2):133-42.
31. van de Poll-Franse LV, Horevoorts N, Schoormans D, Beijer S, Ezendam NP, Husson O, Oerlemans S, Schagen SB, Hageman GJ, Van Deun K, van den Hurk C. Measuring clinical, biological, and behavioral variables to elucidate trajectories of patient-reported outcomes:

the PROFILES Registry. JNCI: Journal of the National Cancer Institute. 2022;114(6):800-7.
32. Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024 Jan 19;103(3):e36905.
33. Obeagu EI, Babar Q, Vincent CC, Udenze CL, Eze R, Okafor CJ, Ifionu BI, Amaeze AA, Amaeze FN. Therapeutic targets in breast cancer signaling: A review. Journal of Pharmaceutical Research International. 2021 Dec 13;33(56A):82-99.
34. Mohamed QH, Obeagu EI. Genetic Heterogeneity in Breast Cancer: Implications. Elite Journal of Health Science. 2024;2(1):20-24.
35. Mohamed AF, Obeagu EI. Genetic Influence on Breast Cancer Progression: A Molecular Perspective. Elite Journal of Medica Science. 2024;2(1):19-22.
36. Obeagu EI, Muhimbura E, Kagenderezo BP, Nakyeyune S, Obeagu GU. An Insight of Interleukin-6 and Fibrinogen: In Regulating the Immune System. J Biomed Sci. 2022;11(10):83.
37. Obeagu EI, Babar Q, Vincent CC, Anyanwu CO, Uduchi IO. Advances in Therapeutic Strategies of Immunotherapy in Cancer Treatment. World Journal of Pharmacy and Pharmaceutical Sciences. 2021;10(8):2144-64.
38. Aizaz M, Khan M, Khan FI, Munir A, Ahmad S, Obeagu EI. Burden of Breast Cancer: Developing Countries Perspective. International Journal of Innovative and Applied Research. 2023;11(1):31-7.
39. Obeagu EI, Obeagu GU. Breast cancer: A review of risk factors and diagnosis. Medicine. 2024 Jan 19;103(3):e36905.
40. Obeagu EI, Obeagu GU. Breastfeeding's protective role in alleviating breast cancer burden: A comprehensive review. Annals of Medicine and Surgery.:10-97.
41. Obeagu EI, Ahmed YA, Obeagu GU, Bunu UO, Ugwu OP, Alum EU. Biomarkers of breast cancer: Overview. Int. J. Curr. Res. Biol. Med. 2023; 1:8-16.
42. Obeagu EI, Obeagu GU. Breaking Ground: PARP Inhibitors and Their Efficacy in Breast Cancer Stages. Elite Journal of Medicine. 2024;2(2):42-54.
43. Obeagu EI, Obeagu GU. BRCA Mastery: Redefining Breast Cancer Care through Cutting-edge Diagnosis and Management. Elite Journal of Medicine. 2024;2(2):55-66.
44. Mohamed QH, Obeagu EI. Genetic Heterogeneity in Breast Cancer: Implications. Elite Journal of Health Science. 2024;2(1):20-24.
45. Mohamed AF, Obeagu EI. Genetic Influence on Breast Cancer Progression: A Molecular Perspective. Elite Journal of Medica Science. 2024;2(1):19-22.